ARS Pharmaceuticals Faces Securities Class Action with October 5 Deadline
A securities class action alleges ARS Pharmaceuticals Inc. made misleading statements. Investors have until October 5, 2026, to join the lawsuit.
A securities class action lawsuit has been filed against ARS Pharmaceuticals Inc. (SPRY), alleging misrepresentations concerning the company's product.
The lawsuit claims ARS Pharmaceuticals made specific, confident statements about a July 1, 2026, CVS Caremark formulary date. Simultaneously, the company allegedly used only generalized risk language, leaving SPRY investors exposed to a 23.9% single-day stock price decline.
Investors who wish to participate in this class action must do so by October 5, 2026. This deadline is a critical date for those considering legal action against the company.
SueWallSt, a law firm focused on representing investors, has reminded shareholders of this deadline. Their allegations center on how ARS Pharmaceuticals presented information regarding the aforementioned date and its associated risks.